BiotechTube

OK-101 0.05% + OK-101 0.1% + Placebo

Phase 2Terminated
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuropathic Pain

Conditions

Neuropathic Pain

Trial Timeline

Oct 15, 2024 → Jul 1, 2025

NCT ID
NCT06637527

About OK-101 0.05% + OK-101 0.1% + Placebo

OK-101 0.05% + OK-101 0.1% + Placebo is a phase 2 stage product being developed by OKYO Pharma for Neuropathic Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT06637527. Target conditions include Neuropathic Pain.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06637527Phase 2Terminated

Competing Products

20 competing products in Neuropathic Pain

See all competitors
ProductCompanyStageHype Score
CHF6467 activeComac MedicalPhase 1/2
33
LY3857210 + PlaceboEli LillyPhase 2
52
YHD1119 + LyricaYuhanPhase 3
77
YHD1119 300mg + YHD1119 300mgYuhanPhase 1
33
pregabalin sustained release tablet + pregabalin immediate release capsuleYuhanApproved
85
DS-5565 + placeboDaiichi SankyoPhase 3
77
Mirogabalin + PlaceboDaiichi SankyoPhase 3
77
DS-1971a + placebo + pregabalinDaiichi SankyoPhase 2
52
DS-5565Daiichi SankyoPhase 3
77
Placebo + MirogabalinDaiichi SankyoPhase 3
77
QutenzaAstellas PharmaPre-clinical
23
Qutenza exposureAstellas PharmaPre-clinical
23
Duloxetine + Pregabalin + PlaceboShionogiApproved
85
LY3016859 + PlaceboEli LillyPhase 2
52
LY3556050 + PlaceboEli LillyPhase 2
52
LY3526318 + PlaceboEli LillyPhase 2
52
LY4065967 + PlaceboEli LillyPhase 2
52
LY3848575 + PlaceboEli LillyPhase 2
52
ABT-639 + pregabalin + PlaceboAbbViePhase 2
52
onabotulinum toxin AAbbViePhase 2
52

Other Products from OKYO Pharma

OK-101 + PlaceboPhase 2
44